Navigation Links
PURE Bioscience Granted US Patent on SDC for Food Treatment
Date:10/30/2008

New Patent Protects PURE in Emerging Food Processing Market for SDC

SAN DIEGO, Oct. 30 /PRNewswire-FirstCall/ -- PURE Bioscience (Nasdaq: PURE) today announced that the United States Patent and Trademark Office issued patent number 7,435,438, which covers PURE's process for treating consumable food products with silver dihydrogen citrate (SDC) to reduce or eliminate microbial contamination. The new patent expands the scope of protection of PURE's core technology patent, US Patent 6,197,814, covering the composition and method of making of PURE's silver dihydrogen citrate (SDC) antimicrobial.

(Logo: http://www.newscom.com/cgi-bin/prnh/20060119/LATH060LOGO)

Michael L. Krall, President and CEO of PURE Bioscience, stated, "Food safety is an ongoing public health concern in the United States, and this new patent provides strategic protection for PURE as we explore applications for SDC in the food processing market with industry leading companies. We continue to build our patent portfolio, both in the US and abroad, to fully protect the numerous potential uses for SDC."

PURE Bioscience's EPA-registered SDC-based disinfectant is a powerful weapon against food borne pathogens, including E. coli, Campylobacter, Listeria, Norovirus and Salmonella. According to information published by the CDC in 2005, known pathogens causing food borne illness account for approximately 14 million illnesses, 60,000 hospitalizations and 1,800 deaths annually in the US.

PURE has four previously granted US patents related to the SDC technology: US Patent 6,197,814 (2001) for the SDC disinfectant and method of its making, Patent 6,583,176 (2003) covering the combination of SDC and alcohol as a disinfectant, Patent 6,890,953 (2005) covering a process for treating water with SDC and Patent 7,261,905 (2007) covering PURE's process of manufacturing complexes of electrolytically generated stabilized ionic silver with various organic acids. PURE also has numerous other patent applications pending in the US, including, among others, coverage of SDC in medical, personal care and preservative applications, the anhydrous - or crystalline - form of SDC, and SDC in combination with traditional chemical disinfectants. In addition, patents have issued or are pending for PURE's SDC technology in approximately 70 countries.

About PURE Bioscience

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at http://www.purebio.com.

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's current and future products and services in the marketplace, the ability of the Company to develop effective new products and receive regulatory approvals of such products, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.

PURE Bioscience Investor Contact:

Paul G. Henning, Vice President

Cameron Associates

(212) 554-5462

paul@cameronassoc.com

PURE Press Contact:

Suzanne Matick

Gutenberg Communications

(831) 479-1888

Suzanne@gutenbergpr.com


'/>"/>
SOURCE PURE Bioscience
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Catalyst Biosciences Appoints Dr. Todd Lorenz Chief Medical Officer
2. Magellan Biosciences Companies to Feature Diagnostic Products Designed to Improve Health Outcomes at the Clinical Lab Expo
3. Senetek Announces Termination of Invicorp(R) License Agreement With Ardana Bioscience Limited
4. Monogram Biosciences Collaborates with Gilead Sciences for Elvitegravir Phase III Studies
5. Monogram Biosciences Announces Immediate Availability of Enhanced Sensitivity Trofile(TM) HIV Tropism Assay
6. Seahorse Bioscience Enters into Agreement with Primetech Corporation to Bring XF Technology to Japanese Market
7. Ardea Biosciences Announces Upcoming Corporate Meetings
8. Ardea Biosciences Reports Progress of Clinical Development Programs; Provides 2008 Outlook; Announces 2007 Financial Results and Provides 2008 Financial Guidance
9. Pressure BioSciences, Inc. Reports 2007 Financial Results and Provides Business Update
10. Pressure BioSciences, Inc. Announces Move to New Corporate Offices
11. Numira Biosciences Names New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at ... company to wait until March 2017 for an interest rate increase, according to Rajeev ... of Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... with discovery of thousands of defective respirators, according to court documents and SEC ... case of William and Becky Tyler v. American Optical Corporation, Case No. BC588866, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, ... as a partner for the Tamika Catchings Legacy Tour that will commemorate ... leader in hardwood basketball surfaces in all forms and levels of the game, Connor ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced two key appointments and ... continued investment and strategic growth plans in the Asia Pacific region. , Howard ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
Breaking Medicine Technology: